Stress-Induced, p53-Mediated Tumor Growth Inhibition of Melanoma by Modulated Electrohyperthermia in Mouse Models without Major Immunogenic Effects
/in Hyperthermia, International Publications, Malignant Melanoma /von 2019-08-17 / Int J Mol Sci 2019 Aug;20(16)A phase II open labeled, randomized study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared to Montanide, in melanoma patients in complete clinical remission.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2019-06-03 / J Clin Oncol 37, 2019 (suppl; abstr 9538)Dendritic cell vaccination in metastatic uveal melanoma as compassionate treatment: Immunological and clinical responses.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e21024)Clinical efficacy of vaccination with the autologous tumor lysate particle loaded dendritic cell (TLPLDC) vaccine in metastatic melanoma.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e21025)Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2019-05-31 / Melanoma Manag 2019 May;6(2):MMT20STAT3 Contributes To Oncolytic Newcastle Disease Virus-Induced Immunogenic Cell Death in Melanoma Cells
/in Immunogenic Cell Death, International Publications, Malignant Melanoma, Newcastle Disease Virus /von 2019-05-29 / Front Oncol 2019;9:436Melanoma vaccines: clinical status and immune endpoints
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2019-04-01 / Melanoma Res. 2019 04;29(2):109-118Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2018-11-21 / Clin Transl Oncol 2019 Jun;21(6):774-780Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Malignant Melanoma, Newcastle Disease Virus /von 2018-10-01 / Am J Clin Dermatol 2018 Oct;19(5):657-670
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de